Bacillus Subtilis-Derived Exopolysaccharide Halts Depigmentation and Autoimmunity in Vitiligo.

Area of Science:

• Immunology
• Microbiology
• Dermatology

Background:

• Vitiligo involves T-cell autoimmunity against melanocytes, with microbial dysbiosis potentially contributing to its etiology.
• Current vitiligo treatments are challenging, necessitating novel therapeutic strategies.
• Exopolysaccharides (EPSs) from Bacillus subtilis are explored as a microbiome-based intervention.

Purpose of the Study:

• To evaluate the efficacy of Bacillus subtilis-derived exopolysaccharides (EPSs) as a potential treatment for vitiligo.
• To investigate the immunomodulatory effects of EPS treatment in a vitiligo mouse model.

Main Methods:

• Vitiligo-prone h3TA2 mice received weekly intraperitoneal injections of EPSs for 18 weeks.
• Depigmentation progression was monitored, and immune responses were assessed at the study's conclusion.
• Flow cytometry and cytokine analysis were used to evaluate T-cell populations, macrophage types, and systemic immune shifts.

Main Results:

• EPS treatment significantly slowed the rate of depigmentation in h3TA2 mice.
• Reduced cutaneous CD8+ cytotoxic T cells and increased regulatory T cells were observed in treated mice.
• EPS therapy promoted M2 macrophages, elevated indoleamine 2,3-dioxygenase, and shifted cytokines towards a type 2 pattern, dampening T-cell responses to tyrosinase peptide.

Conclusions:

• Bacillus subtilis EPS demonstrated immunomodulatory effects, interfering with T-cell-mediated depigmentation in a vitiligo mouse model.
• These findings suggest that Bacillus subtilis EPS could be a novel therapeutic agent for vitiligo treatment.
• Microbiome-based therapies hold potential for managing autoimmune skin conditions like vitiligo.